Medical EMC Test — IEC 60601-1-2

What Is EMC IEC 60601-1-2?

The IEC 60601-1-2 test verifies that medical electrical equipment does not emit unacceptable electromagnetic interference into its surroundings, and itself retains essential performance under interference. What differs from general EMC standards is that immunity requirements are tied to the device's ESSENTIAL PERFORMANCE: in a patient monitor, display distortion and loss of an alarm do not carry the same weight.

Purpose of EMC IEC 60601-1-2

The purpose is to show that the device does not endanger patient safety due to electromagnetic interference in the environment where it will be used (hospital, home, emergency department).

Which Products Is EMC IEC 60601-1-2 Applied To?

Patient monitors and diagnostic devices
Infusion pumps
Imaging systems
Home-use medical devices
Wirelessly connected medical devices

In Which Sectors Is EMC IEC 60601-1-2 Used?

Medical DeviceHealthcarePharmaceuticals

Standards Related to EMC IEC 60601-1-2

IEC 60601-1-2electromagnetic compatibility in medical electrical devices test
CISPR 11
IEC 61000-4 series
IEC 60601-1Basic safety in medical electrical devices test
ISO 11607end product sterile barrier packaging test

EMC IEC 60601-1-2 Conditions

Use environment: Professional healthcare facility, home environment, or special environment; immunity levels are determined accordingly
Essential performance: Defined by the manufacturer; the immunity acceptance criterion is based on this
Emission class: Group and Class are determined under CISPR 11

Equipment for EMC IEC 60601-1-2

Semi-anechoic EMC chamber
LISN and conducted-emission measurement system
ESD generator
EFT/burst and surge generators
RF field-generation system and antenna set
Magnetic-field generation coil
Device monitoring and essential-performance verification rig

Sample Requirements for EMC IEC 60601-1-2

The final product and all its accessories
Patient simulator or suitable load
The essential-performance definition and monitoring method must be determined
Cable configuration must represent real use
Reference to the risk management file must be provided

Duration of EMC IEC 60601-1-2

A complete EMC campaign typically takes 1–3 weeks; pre-compliance testing shortens the process.

EMC IEC 60601-1-2 Procedure

1Essential performance and the monitoring method are defined.
2The use environment is determined and the levels to be applied are chosen.
3Radiated and conducted emission measurements are performed.
4The ESD immunity test is applied.
5Radiated and conducted RF immunity tests are carried out.
6EFT, surge, voltage-dip and magnetic-field tests are performed.
7Essential performance is monitored during each test.
8Results are compared with the limits and acceptance criteria.

EMC IEC 60601-1-2 Acceptance Criteria

The emission acceptance criteria are CISPR 11's relevant group and class limits. On the immunity side, acceptance is the device not losing essential performance and not creating unacceptable risk; the performance criterion is defined by the manufacturer and based on risk analysis.

Evaluation of Results

Immunity results are interpreted through the essential-performance definition. If this definition is written too narrowly, the device passes easily but does not reflect the real risk; the notified body questions the rationale for this definition.

EMC IEC 60601-1-2 Report

Device description and use environment
Essential-performance definition and monitoring method
Applied standard edition and test levels
Emission measurement results and limit comparison
Immunity test results and observations
Cable and configuration information

Accreditation

EUROLAB holds internationally recognised accreditation obtained from accreditation bodies party to the IAF and ILAC multilateral recognition arrangements, under ISO/IEC 17025 for laboratory testing, ISO/IEC 17020 for inspection and surveillance, and ISO/IEC 17021-1 and ISO/IEC 17065 for system and product certification. This chain ensures the reports and certificates issued are accepted worldwide.

Whether this test can be offered within accredited scope depends on your product and the standard applied; since accreditation is method-based, the scope is confirmed in writing at the quotation stage.

Scope and authorisations

Related Regulations

MDR (EU) 2017/745
Relationship with the EMC Directive

Medikal Cihaz Testleri — What Does This Testing Field Cover?

The section below describes the field that the EMC IEC 60601-1-2 test belongs to; the conditions and acceptance criteria of this particular test are given in the sections above. The scope specific to your product is confirmed in writing at the quotation stage.

Medical device testing shows that a device is safe for the patient and the user and maintains its intended performance. In this family safety is not only about avoiding harm; a device failing to perform its expected function is also treated as a risk. A monitor missing an alarm or a pump delivering the wrong dose is directly a patient safety event.

At the centre of the field is RISK MANAGEMENT, and this is what sets medical apart from other sectors. The risk management process run under ISO 14971 also determines which tests are required. The test list is not copied from a table of standards; it is derived and justified from the device's intended use, the nature and duration of patient contact, the use environment and foreseeable misuse.

Assessment consists of several separate bodies of work, each with its own set of standards. Biocompatibility runs through the ISO 10993 series, electrical device safety through the IEC 60601 series, sterilisation through ISO 11135/11137/17665, packaging through ISO 11607, software through IEC 62304 and usability through IEC 62366. The quality system (ISO 13485) is the framework that binds these together.

Which tests are required is determined by the device's CLASS and its MODE OF CONTACT WITH THE BODY. A product in brief contact with skin and an implant entering the bloodstream do not go through the same test set; the scope is set by a biological evaluation plan prepared under ISO 10993-1. That plan justifies in writing which endpoints are required and why the others are not.

Packaging and sterilisation are taken as seriously as the device itself in this field. For a sterile device the packaging is not a transport container but the barrier that maintains sterility; if the barrier is breached, the device is no longer sterile. Packaging processes are therefore validated and shelf life is supported by real-time ageing data.

For devices containing software, assessment shifts from testing towards PROCESS assurance. IEC 62304 defines which development and verification steps must be followed according to the safety class of the software; the evidence is the traceability of the development process. Testing software does not make it safe — the process record does.

The clinical side is a separate column of the technical file. Test reports show that the device is technically safe; clinical evaluation establishes that the device delivers the intended clinical benefit and that the benefit-risk balance is acceptable. Neither replaces the other.

Method groups in this field

Biocompatibility
Cytotoxicity, irritation, skin sensitisation, systemic toxicity, haemocompatibility, genotoxicity and local effects after implantation. The required endpoints are set by the ISO 10993-1 plan.
Electrical device safety
IEC 60601-1 basic safety and essential performance; EMC, alarm, usability and environmental requirements through the collateral standards.
Sterilisation validation
Validation of sterilisation processes by ethylene oxide, radiation or moist heat; bioburden and sterility assurance level studies.
Packaging
Integrity of the sterile barrier system, seal strength, distribution simulation and shelf-life studies.
Microbiological tests
Bioburden determination, sterility testing, bacterial endotoxin and, where required, carrier validation studies.
Software and usability
IEC 62304 life cycle evidence and use-error focused evaluation under IEC 62366.

Commonly confused in this field

Cytotoxicity alone is not evidence of biocompatibility; the required set of endpoints is determined and justified according to ISO 10993-1.
An ISO 13485 certificate does not confer CE marking; classification under the MDR, the technical file and the notified body process run separately.
Accelerated ageing does not replace real-time ageing; a shelf life claim is supported by real-time data.
A change of material (supplier, pigment, sterilisation method) may require the biological evaluation to be repeated; it is not a silent change.
An assessment made without the collateral and particular standards for IEC 60601-1 is incomplete; which -1-x and -2-x standards were applied must appear in the report.
In vitro diagnostic devices fall under the IVDR rather than the MDR, and laboratory equipment is often on the IEC 61010-1 side.

Which decisions these results support

MDR/IVDR technical file and notified body assessment
Completing the biological evaluation plan
Sterilisation and packaging validation
Determining shelf life and storage conditions
Determining the scope of reassessment after a design change

Related Tests

Frequently Asked Questions About EMC IEC 60601-1-2

How should I define essential performance?

It is defined as the performance characteristic whose loss would create unacceptable risk to the patient, and is derived from risk analysis. For example, a monitor's ability to produce an alarm is essential performance; a transient change in screen brightness generally is not. The rationale for the definition must be included in the risk file.

Does my wireless-enabled device also need RED?

In the EU market, medical devices containing a radio module can fall under both MDR and RED. In that case, radio-spectrum requirements are addressed through RED, and medical safety and performance requirements through MDR; the two regimes run in parallel.